Kymera Therapeutics annual ebitda margin
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics EBITDA Margin Growth & History (KYMR)
Kymera Therapeutics's ebitda margin was −869.87% for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −869.87% | −329.72 pp |
| 2024 | 2024-12-31 | −540.16% | −334.07 pp |
| 2023 | 2023-12-31 | −206.08% | +131.93 pp |
| 2022 | 2022-12-31 | −338.02% | −203.28 pp |
| 2021 | 2021-12-31 | −134.74% | −3.87 pp |
| 2020 | 2020-12-31 | −130.87% | +1279.49 pp |
| 2019 | 2019-12-31 | −1,410.36% | — |
Kymera Therapeutics quarterly ebitda margin
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −113.20% | +605.46 pp |
| Q1 2026 | 2026-03-31 | −239.00% | +88.50 pp |
| Q4 2025 | 2025-12-31 | −3,339.01% | −2273.71 pp |
| Q3 2025 | 2025-09-30 | −3,269.61% | −1394.79 pp |
| Q2 2025 | 2025-06-30 | −718.66% | −527.67 pp |
| Q1 2025 | 2025-03-31 | −327.50% | +220.47 pp |
| Q4 2024 | 2024-12-31 | −1,065.30% | −1026.83 pp |
| Q3 2024 | 2024-09-30 | −1,874.82% | −677.40 pp |
| Q2 2024 | 2024-06-30 | −190.98% | +66.29 pp |
| Q1 2024 | 2024-03-31 | −547.97% | −78.43 pp |
| Q4 2023 | 2023-12-31 | −38.47% | +195.83 pp |
| Q3 2023 | 2023-09-30 | −1,197.42% | −735.53 pp |
| Q2 2023 | 2023-06-30 | −257.27% | +91.05 pp |
| Q1 2023 | 2023-03-31 | −469.54% | −92.84 pp |
| Q4 2022 | 2022-12-31 | −234.30% | −16.26 pp |
| Q3 2022 | 2022-09-30 | −461.89% | −324.37 pp |
| Q2 2022 | 2022-06-30 | −348.32% | −217.76 pp |
| Q1 2022 | 2022-03-31 | −376.70% | −308.88 pp |
| Q4 2021 | 2021-12-31 | −218.04% | −121.95 pp |
| Q3 2021 | 2021-09-30 | −137.52% | −85.27 pp |
| Q2 2021 | 2021-06-30 | −130.56% | +289.24 pp |
| Q1 2021 | 2021-03-31 | −67.82% | +248.98 pp |
| Q4 2020 | 2020-12-31 | −96.09% | — |
| Q3 2020 | 2020-09-30 | −52.25% | +1166.81 pp |
| Q2 2020 | 2020-06-30 | −419.80% | — |
| Q1 2020 | 2020-03-31 | −316.80% | — |
| Q3 2019 | 2019-09-30 | −1,219.05% | — |
Kymera Therapeutics ebitda margin trends
Over the last five fiscal years, Kymera Therapeutics's ebitda margin decreased from −130.87% to −869.87%, a change of −739.00 percentage points. The latest reported quarter, Q2 2026, shows −113.20%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗Community posts
Kymera reports early human results for oral IRF5 drug
Kymera ($KYMR) reported results from its first human study of KT-579, an experimental oral medicine targeting the immune regulator IRF5. In healthy volunteers receiving repeated doses, median blood IRF5 reductions reached at least 90% acros ...
